Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23269
Title: Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Authors: Gleeson, Mary;Counsell, Nicholas;Cunningham, David;Lawrie, Anthony;Clifton-Hadley, Laura;Hawkes, Eliza A;McMillan, Andrew;Ardeshna, Kirit M;Burton, Cathy;Chadwick, Nick;Gambell, Joanna;Smith, Paul;Mouncey, Paul;Pocock, Christopher;Radford, John;Davies, John;Turner, Deborah;Kruger, Anton;Johnson, Peter;Linch, David
Affiliation: Guy's and St Thomas' NHS Foundation Trust, London, UK
Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Mount Vernon Cancer Centre, Northwood, UK
Western General Hospital, Edinburgh, UK
Cancer Research UK Centre, Southampton, UK
The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
East Kent Hospitals, Canterbury, UK
HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Nottingham City Hospital, Nottingham, UK
The Royal Marsden Hospital, London and Surrey, London, UK
Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK
University College London, London, UK
Royal Cornwall Hospital, Truro, UK
Torbay Hospital, Torquay, UK
The Royal Marsden Hospital, London and Surrey, London, UK
University College London, London, UK
Eastern Health, Melbourne, Australia
Issue Date: 20-May-2020
EDate: 2020-05-20
Citation: British journal of haematology 2020; online first: 20 May
Abstract: We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23269
DOI: 10.1111/bjh.16691
ORCID: 0000-0001-6915-9878
0000-0002-0376-2559
0000-0002-9988-5528
PubMed URL: 32436212
Type: Journal Article
Subjects: clinical trials
diffuse large B-cell lymphoma
international prognostic index
rituximab
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.